Drug
Empasiprubart
Empasiprubart: highest development phase Phase 3, developed by Argenx. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Empasiprubart NCT06742190 | Phase 3 | Multifocal Motor Neuropathy (MMN) |
| Empasiprubart IV NCT07091630 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy |
| empasiprubart NCT06920004 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy |
| Empasiprubart IV NCT07821762 | Phase 2 | Guillain-Barré Syndrome (GBS) |
| Empasiprubart IV NCT06284954 | Phase 2 | Dermatomyositis |
| Empasiprubart IV NCT07673627 | Phase 2 | AChR-Ab Seropositive Generalized Myasthenia Gravis |
| Empasiprubart IV NCT07610564 | Phase 1 | Multifocal Motor Neuropathy (MMN) |
Latest
No recent events.
Follow Empasiprubart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.